Your browser doesn't support javascript.
loading
Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice.
Amé, Shanti; Barraco, Fiorenza; Ianotto, Jean-Christophe; Jourdan, Eric; Rey, Jérôme; Viallard, Jean-François; Wémeau, Mathieu; Kiladjian, Jean-Jacques.
Afiliação
  • Amé S; Department of Haematology Institut de Cancérologie Strasbourg Europe (ICANS) Strasbourg France.
  • Barraco F; Department of Haematology Lyon Sud Hospital Centre Pierre-Bénite France.
  • Ianotto JC; Department of Clinical Haematology University Hospital of Brest Brest France.
  • Jourdan E; Department of Clinical Haematology University Hospital of Nimes Nimes France.
  • Rey J; Department of Haematology Institute Paoli-Calmettes Marseille France.
  • Viallard JF; Department of Internal Medicine Bordeaux University Hospital Bordeaux France.
  • Wémeau M; Department of Haematology Hospital Centre of Roubaix Roubaix France.
  • Kiladjian JJ; Centre d'Investigations Cliniques Hôpital Saint-Louis, Université Paris Cité Paris France.
EJHaem ; 4(3): 779-791, 2023 Aug.
Article em En | MEDLINE | ID: mdl-37601853
ABSTRACT
Primary myelofibrosis (PMF) and polycythaemia vera (PV) are rare BCR-ABL1-negative myeloproliferative neoplasms, associated with an increased risk of thrombosis, haemorrhagic complications and progression to fibrosis or leukaemia or fibrosis for PV. Both diseases are characterised by biological and clinical heterogeneity, leading to great variability in their management in routine clinical practice. In this review, we present an updated overview of the diagnosis, prognosis and treatment of PMF and PV, and we discuss how our multidisciplinary expert group based across France translates this evidence-based knowledge into routine clinical practice.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article